More specifically, targeting CDK1 has shown efficacy in disrupting these pathways by inducing phosphorylation of HIF-1α or through lysosome-inducing degradation of HIF-1α, leading to reduced tumor growth and viability (29). The gene discussed is HIF1A; the disease is neoplasm.